The DKMS-BMST Thalassemia program: Description, scope and impact
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only established curative therapy for thalassemia. However, access to transplantation is constrained in limited-resource settings. Human leukocyte antigen (HLA) typing of patients and potential donors is one relevant barrier to al...
Saved in:
Main Authors: | Nitin Agarwal (Author), K. Jothi (Author), Shalini Gambhir (Author), Gabi Rall (Author), Regina Landwehr (Author), Lawrence Faulkner (Author), Latha Jagannathan (Author), Patrick Paul (Author), Alexander H. Schmidt (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
DKMS Access to Transplant (ATT) programme: Giving hope for a healthy future
by: Reshma Kumari, et al.
Published: (2024) -
Allogenic bone marrow transplantation in thalassemia major: Our experience
by: Vaibhav Shah, et al.
Published: (2022) -
Losing the genetic twin: donor grief after unsuccessful unrelated stem cell transplantation
by: Rall Gabi, et al.
Published: (2009) -
Low-cost matched sibling bone marrow transplant for standard-risk thalassemia in a limited-resource setting
by: Stalin Ramprakash, et al.
Published: (2017) -
Role of G-CSF priming of donor marrow prior to transplant in low risk HLA matched sibling transplant in children with severe thalassemia
by: Stalin Ramprakash, et al.
Published: (2017)